Actithera, a pioneering radiopharmaceutical biotech based in Oslo and Cambridge, secured nearly $76 million in Series A financing to progress its novel cancer therapy pipeline targeting fibroblast activation proteins. The company's approach aims to dismantle tumor-supporting fibroblasts, enhancing immune access to tumors. This financing round, co-led by M Ventures and Hadean Ventures among others, underscores growing investor interest in radiopharma technologies following successes like Novartis' Pluvicto. Despite manufacturing and logistical challenges inherent to radiopharmaceuticals, Actithera’s focused drug design seeks longer tumor retention for improved therapeutic outcomes.